Please assess the completion status of the following clinical trial:

Trial Title: Study 302: BLI4900 Versus an FDA-approved Comparator in Adult Subjects Prior to Colonoscopy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female outpatients who are undergoing colonoscopy for a routinely accepted indication.~* 18 to 85 years of age (inclusive)~* If female, and of child-bearing potential, is using an acceptable form of birth control.~* Negative serum pregnancy test at screening, if applicable~* In the Investigator's judgment, subject is mentally competent to provide informed consent to participate in the study~Exclusion Criteria:~* Subjects with known or suspected ileus, gastrointestinal obstruction, gastroparesis, gastric retention, bowel perforation, toxic colitis or megacolon.~* Subjects with inflammatory bowel disease who have a history of any bowel resection (small intestine or colon), suspected active inflammation, or symptoms suggestive of obstruction or known bowel stricture.~* Subjects who had previous significant gastrointestinal surgeries.~* Subjects who have regularly used laxatives or colon motility altering drugs in the last month (i.e. more than 2-3 times per week) and/or laxative use within 72 hours prior to administration of the preparation~* Subjects with uncontrolled pre-existing electrolyte abnormalities, or those with clinically significant electrolyte abnormalities based on Visit 1 laboratory results.~* Subjects taking diuretics, anti-hypertensive medications, including angiotensin converting enzyme (ACE) inhibitors and Angiotensin II receptor blockers (ARBs), or chronic NSAIDs, that have not been stable for 30 days.~* Subjects with uncontrolled hypertension.~* Subjects taking antibiotics within 7 days of colonoscopy.~* Subjects with severe renal, hepatic or cardiac insufficiency.~* Subjects with an abnormal and clinically significant physical examination or ECG finding at Visit 1.~* Subjects undergoing insulin therapy for any indication.~* Subjects with impaired consciousness that predisposes them to pulmonary aspiration.~* Subjects undergoing colonoscopy for foreign body removal and/or decompression.~* Subjects taking tricyclic antidepressants.~* Subjects using drugs of abuse, including abused prescription medications.~* Subjects who are withdrawing from alcohol or benzodiazepines.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- BLI4900 (Type: EXPERIMENTAL): Experimental bowel preparation solution for oral ingestion
- FDA Approved Control (Type: ACTIVE_COMPARATOR): FDA approved bowel preparation solution for oral ingestion

Based on this trial design, predict the completion outcome and termination type (if applicable).